Key Takeaway
No, retatrutide isn't currently available for prescription. Learn about its Phase 3 clinical trial status, expected availability timeline, and what options exist today.
No, retatrutide isn't currently available for prescription. It remains in Phase 3 clinical trials under Eli Lilly's TRIUMPH program and hasn't yet been submitted to the FDA for approval. You can't get retatrutide from a pharmacy, a telehealth provider, or a legitimate compounding pharmacy at this time. Any source claiming to sell retatrutide today is operating outside of regulatory approval, and purchasing from such sources carries serious health risks.
This is an important distinction to make clearly, because the excitement around retatrutide's clinical trial results has fueled a surge in online interest and, unfortunately, a wave of misleading claims from unregulated sellers.
Where Retatrutide Stands Right Now
As of early 2026, retatrutide is in the middle of its Phase 3 clinical trial program. Eli Lilly is running multiple large-scale trials under the TRIUMPH umbrella, studying the drug in patients with obesity, type 2 diabetes, and related conditions. These trials involve thousands of participants at clinical sites around the world.
Phase 3 is the final stage of clinical testing before a pharmaceutical company can apply for FDA approval. The trials typically run for 36 to 72 weeks per participant, followed by data analysis, report compilation, and formal submission to the FDA. After submission, the FDA review process itself takes an additional 6 to 10 months.
Based on this timeline, the earliest realistic date for FDA approval is late 2027, with early 2028 being the more conservative and likely estimate. Even after approval, it takes additional time for the drug to reach pharmacies, get added to insurance formularies, and become widely available to patients.
Can You Get Retatrutide Through Clinical Trials?
The only legitimate way to access retatrutide right now is by participating in a clinical trial. Eli Lilly's TRIUMPH trials are enrolling patients at select medical centers. But clinical trial participation comes with important caveats.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
First, you must meet specific eligibility criteria. Each trial has its own requirements related to BMI, medical history, age, and other health factors. Not everyone who wants to participate will qualify.
Second, most Phase 3 trials are randomized and placebo-controlled. That means there's a real chance you could be assigned to the placebo group and not receive the active drug at all. You won't know which group you're in until the trial is complete.
Third, trial participation requires regular visits to the study site for monitoring, blood work, and assessments. This is a significant time commitment that not everyone can accommodate.
If you're interested in participating, you can search for active retatrutide trials on ClinicalTrials.gov or ask your doctor whether any local medical centers are enrolling participants.
Beware of Online Sellers
The internet is full of websites and social media accounts claiming to sell retatrutide. Some market it as a "research chemical" or "peptide" available for purchase. Others frame it as a compounded version available through telehealth consultations. These claims should raise immediate red flags.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →Retatrutide has no FDA approval in any form. It isn't available as a branded drug, a generic, or a compounded medication. Under current FDA regulations, compounding pharmacies can only produce copies of drugs that have an approved reference product and are in shortage. Retatrutide meets neither of these conditions.
Products sold as retatrutide from unregulated sources carry multiple risks:
- Unknown purity and potency: Without FDA oversight, there's no guarantee that the product contains what the label claims. It could be underdosed, overdosed, or contain harmful contaminants.
- No medical supervision: Retatrutide is a potent triple-hormone agonist that requires careful dose titration. Using it without proper medical monitoring is dangerous.
- Legal risk: Purchasing unapproved pharmaceutical products can carry legal consequences depending on your jurisdiction.
- Financial fraud: Many of these sellers operate with minimal accountability. Refund policies are often nonexistent, and customer service disappears quickly.
The safest approach is to wait for FDA approval and obtain retatrutide through a licensed prescriber and pharmacy when the time comes.
What Can You Do in the Meantime?
If you're interested in GLP-1 based weight management today, there are FDA-approved options available right now. Semaglutide (marketed as Wegovy for weight loss and Ozempic for type 2 diabetes) and tirzepatide (marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes) are both prescribed by doctors across the country.
These medications have established safety profiles, known dosing protocols, and are available through standard pharmacies. While their weight loss results aren't as dramatic as what retatrutide showed in Phase 2 trials, they still represent a significant advancement over older weight management approaches.
Semaglutide produces average weight loss of about 15% of body weight, while tirzepatide averages around 22.5% at its highest dose. Both are injectable medications administered once weekly, similar to how retatrutide will likely be dosed.
Starting with one of these approved medications now doesn't prevent you from switching to retatrutide once it becomes available. In fact, building a relationship with a prescriber who specializes in obesity medicine positions you well to transition to newer treatments as they come to market.
When Will Availability Change?
The answer depends on how smoothly the remaining clinical development process goes. If Eli Lilly's Phase 3 trials produce strong results with no unexpected safety concerns, and the company moves quickly to file its NDA, a late 2027 approval is possible. Commercial availability would follow weeks to months after approval, depending on manufacturing readiness and supply chain preparation.
Eli Lilly has experience finding this process. The company's launch of tirzepatide (Mounjaro/Zepbound) provides a useful reference point. But that launch was also accompanied by significant supply shortages that persisted for over a year. Patients hoping for smooth access to retatrutide from day one should temper their expectations accordingly.
We will update this page as the regulatory space evolves. For now, the key point is clear: retatrutide isn't available today, and any claim to the contrary should be treated with extreme caution.